Clinical trial
A Study to Evaluate Patient Preference and Satisfaction of Subcutaneous…
NCT03674112 · Hoffmann-La Roche, Industry · Completed
Key facts
| NCT number | NCT03674112 |
|---|---|
| Title | A Study to Evaluate Patient Preference and Satisfaction of Subcutaneous Administration of the Fixed-Dose Combination of Pertuzumab and Trastuzumab in Participants With HER2-Positive Early Breast Cancer |
| Official title | A Randomized, Multicenter, Open-Label Cross-Over Study to Evaluate Patient Preference and Satisfaction of Subcutaneous Administration of the Fixed-Dose Combination of Pertuzumab and Trastuzumab in Patients With HER2-Positive Early Breast Cancer |
| Acronym | PHranceSCa |
| Lead sponsor | Hoffmann-La Roche, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | HER2-Positive Early Breast Cancer |
| Intervention type | Drug |
| Interventions | Pertuzumab and Trastuzumab Fixed-Dose Combination for Subcutaneous Administration (PH FDC SC), Pertuzumab IV, Trastuzumab IV |
| Enrollment | 160 |
| Start date | Dec 19, 2018 |
| Primary completion | Feb 24, 2020 |
| Completion | Oct 12, 2022 |
| First posted | Sep 17, 2018 |
| Last update posted | Jan 2, 2024 |
| Countries | Argentina, Brazil, Chile, Cuba, Finland, Hong Kong, Jordan, Lebanon, Mexico, Panama, Portugal, Qatar and 5 more |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: